{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:41:58Z","timestamp":1790095318345,"version":"4.0.1"},"reference-count":17,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2022,1,9]]},"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:p>Mesalazine is often used as first-line therapy for ulcerative colitis. Several reports have pointed to systemic adverse reactions associated with this drug. Most have evoked a drug-induced hypersensitivity syndrome, while some have described lupus syndromes but with limited clinical and varied biological features. A 75-year-old man presented with fever, dyspnoea, chest pain, polyarthralgia, and myalgia, following mesalazine introduction. Clinical symptoms and low-titre positive antihistone antibodies disappeared after mesalazine withdrawal without recourse to steroids. Pericardial effusion and 8F-fluorodeoxyglucose uptake on positron emission tomography\/CT scan, and glomerular haematuria and proteinuria also disappeared. Cytokine-lymphocyte transformation tests showed a strong sensitisation pattern with interleukin-5 production. This case advances our knowledge of the mechanism of mesalazine-induced adverse effects, namely via drug-induced hypersensitivity with lupus manifestations, which we are the first to report.<\/jats:p>","DOI":"10.1136\/bcr-2021-248229","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T11:33:12Z","timestamp":1645788792000},"page":"e248229","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Drug-induced hypersensitivity syndrome with lupus manifestations due to mesalazine in a patient with ulcerative colitis"],"prefix":"10.1136","volume":"15","author":[{"given":"Omar","family":"Zgheib","sequence":"first","affiliation":[{"name":"Internal Medicine of the Elderly, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Trombert","sequence":"additional","affiliation":[{"name":"Internal Medicine of the Elderly, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Jandus","sequence":"additional","affiliation":[{"name":"Immunology and Allergology, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Serratrice","sequence":"additional","affiliation":[{"name":"Internal Medicine of the Elderly, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"2025082708460734000_15.2.e248229.1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-79207-z","article-title":"Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease","volume":"10","author":"Matsumoto","year":"2020","journal-title":"Sci Rep"},{"key":"2025082708460734000_15.2.e248229.2","doi-asserted-by":"crossref","first-page":"466","DOI":"10.4212\/cjhp.v69i6.1610","article-title":"5-Aminosalicylic acid-associated myocarditis and pericarditis: a narrative review","volume":"69","author":"Brown","year":"2016","journal-title":"Can J Hosp Pharm"},{"key":"2025082708460734000_15.2.e248229.3","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009688","article-title":"Drug-induced eosinophilic pneumonia: a review of 196 case reports","volume":"97","author":"Bartal","year":"2018","journal-title":"Medicine"},{"key":"2025082708460734000_15.2.e248229.4","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-019-1049-2","article-title":"The culprit of mesalamine intolerance: case series and literature review","volume":"19","author":"Xie","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"2025082708460734000_15.2.e248229.5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.305.6846.159-b"},{"key":"2025082708460734000_15.2.e248229.6","first-page":"586","article-title":"Mesalazine-induced lupus","volume":"64","author":"Timsit","year":"1997","journal-title":"Rev Rhum Engl Ed"},{"key":"2025082708460734000_15.2.e248229.7","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0248-8663(00)87532-3","article-title":"Lupus et macrocr\u00e9atine phosphokinase induits par la m\u00e9salazine: propos d'un cas [Lupus and macrocreatine phosphokinase induced by mesalazine: a case report]","volume":"20","author":"Granel","year":"1999","journal-title":"Rev Med Interne"},{"key":"2025082708460734000_15.2.e248229.8","doi-asserted-by":"publisher","DOI":"10.1177\/096120339900800616"},{"key":"2025082708460734000_15.2.e248229.9","first-page":"159","article-title":"Lupus-like syndrome caused by 5-aminosalicylic acid in patients with inflammatory bowel disease","volume":"13","author":"Kirkpatrick","year":"1999","journal-title":"Can J Gastroenterol"},{"key":"2025082708460734000_15.2.e248229.10","first-page":"309","article-title":"Lupus induit PAR La m\u00e9salazine","volume":"65","author":"Maillefert","year":"1998","journal-title":"Rev Rhum"},{"key":"2025082708460734000_15.2.e248229.11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jaci.2018.09.022","article-title":"Controversies in drug allergy: In vitro testing","volume":"143","author":"Mayorga","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2025082708460734000_15.2.e248229.12","article-title":"[Acute renal failure secondary to DRESS syndrome]","volume":"36","author":"Rahbari","year":"2019","journal-title":"G Ital Nefrol"},{"key":"2025082708460734000_15.2.e248229.13","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.2169\/internalmedicine.55.5694","article-title":"Drug-Induced hypersensitivity syndrome accompanied by pulmonary lesions exhibiting centrilobular nodular shadows","volume":"55","author":"Sawata","year":"2016","journal-title":"Intern Med"},{"key":"2025082708460734000_15.2.e248229.14","first-page":"559","article-title":"Skojarzenie wystepowania wrzodziejacego zapalenia jelita grubego z nefropatia toczniowa - analiza kliniczna dw\u00f3ch przypadk\u00f3w chorobowych [Association of ulcerative colitis and lupus nephropathy-report of two cases]","volume":"115","author":"Nieradko-Iwanicka","year":"2006","journal-title":"Pol Arch Med Wewn."},{"key":"2025082708460734000_15.2.e248229.15","doi-asserted-by":"publisher","DOI":"10.1097\/fpc.0000000000000350"},{"key":"2025082708460734000_15.2.e248229.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05838.x"},{"key":"2025082708460734000_15.2.e248229.17","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s12328-021-01341-6","article-title":"Peri-myocarditis caused by topical rectal mesalamine","volume":"14","author":"Koslowsky","year":"2021","journal-title":"Clin J Gastroenterol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-248229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:46:14Z","timestamp":1756309574000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-248229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":17,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,25]]},"published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1136\/bcr-2021-248229"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-248229","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}